???We are delighted about being chosen for this collaboration,??? said Prof. Melvyn Little, Chief Scientific Officer of Affimed. ???Affimed???s antibody discovery engine is one of the most powerful in industry and we are confident that with this funding we will be able to generate novel tumour specific binding proteins that may have diagnostic or even therapeutic use.???